This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 97 cents for the third quarter of fiscal 2010, well above the Zacks Consensus Estimate of 86 cents. Total revenues increased 6.7% to $1.06 billion with product revenues increasing 8.4% to $997 million.

Although Lexapro sales declined 0.5% to $582.6 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $282.5 million, recording a growth of 17.3% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong.

Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $47.5 million. This was significantly higher than the year-ago sales of $21 million. Contract revenue, consisting primarily of Benicar co-promotion income, increased 6.5% to $55.8 million.

Forest’s most recent product launch, Savella, which is approved for the management of fibromyalgia, posted sales of $15.4 million. The product, which has

...

AstraZeneca’s (AZN) third quarter earnings came in at $1.68 per American Depositary Shares (ADS), well above the Zacks Consensus Estimate of $1.36 and $1.32 reported in the year-ago period. Revenues increased 10% at constant exchange rates (CER) to $8.2 billion compared to the same period last year. The primary reasons for the increase in revenues were strong US sales of Toprol-XL benefiting from generic withdrawal, US sales of its H1N1 vaccine and robust growth in emerging markets. AstraZeneca recorded strong sales across all geographies. Sales in North America, Emerging Markets and Established Markets increased (at CER) by 13%, 15% and 4%, respectively. The company expects double-digit revenue growth in Emerging Markets for the full year. Among the product categories, apart from gastrointestinal and oncology, which recorded sales decline of 1% and 10% respectively, all other segments increased their revenues. AstraZeneca recorded more than 26% of ...

DrStockPick.com Stock Report!

Wednesday August 12, 2009

**************************************************************

Cisco (NASDAQ: CSCO) and AIESEC, the world’s largest student-run organization, have launched an innovative program to provide Malaysian students with the opportunity to expand their skills and gain valuable international work experience. The initiative is in line with the Malaysian government’s call for more public-private sector collaboration to support the education and development of a highly skilled, technology-savvy workforce that can compete in the global arena.

The Bank of New York Mellon Corporation (NYSE: BK) announced it has agreed to acquire Insight Investment Management Limited (”Insight Investment”) from Lloyds Banking Group plc for 235 million pounds Sterling. Based in London, Insight Investment specialises in LDI (Liability

...

For Immediate Release

Chicago, IL - June 29, 2009 - Zacks Equity Research highlights Strayer Education (STRA) as the Bull of the Day and Red Robin Gourmet Burgers (RRGB) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Forest Laboratories, Inc. (FRX), ViroPharma (VPHM) and Pfizer (PFE).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day:

Financial results for the past thirteen quarters at Strayer Education (STRA) have been above expectations, and management's guidance for 2009 portends continued double-digit EPS growth.

The company benefits from positive pricing through annual 5% tuition increases with the 2009 tuition increase having been announced concurrent with the third quarter earnings report.

Despite the stock's valuation being in

...

Positive Top-Line Data on CeftarolineForest Laboratories, Inc. (FRX) announced positive results recently from two global multi-center phase III studies which were conducted to evaluate the efficacy, safety and tolerability of ceftaroline for the treatment of community-acquired bacterial pneumonia (CABP).The top-line data in each of the studies (FOCUS I and II) showed that ceftaroline met the primary endpoint of non-inferiority and achieved high clinical cure rates compared with ceftriaxone (84.3% vs. 77.7%). Additionally, ceftaroline was well tolerated with an adverse event profile similar to ceftriaxone. Earlier, Forest had reported positive phase III results on ceftaroline for the treatment of complicated skin and skin structure infections (cSSSI).Ceftaroline is a novel, bactericidal, injectable, broad-spectrum cephalosporin which is being developed for the treatment of cSSSI and CABP. The anti-infective market, which is currently dominated by antibiotics, ...